New Therapeutic Developments in Urothelial Cancer: Clinical Trial Evidence and Expert Guidance

New Therapeutic Developments in Urothelial Cancer: Clinical Trial Evidence and Expert Guidance

Monday, June 22, 2020
Webinar -- 6:30 PM ET
http://www.clinicaloptions.com/Summer2020BladderJoin

Agenda

Welcome and Introduction

Case Discussions:

  • Challenges in Selecting First-line Therapy for Urothelial Carcinoma
  • Current Clinical Experience and New Therapeutic Directions for Second and Subsequent Lines of Therapy

Ongoing Research and New Horizons for UC

Audience Question and Answer Session and Final Thoughts

Faculty

Program Director
Daniel P. Petrylak, MD, PhD

Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, Connecticut

Faculty
Matthew I. Milowsky, MD

Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Faculty
Jonathan E. Rosenberg, MD

Associate Attending Physician
Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate new agents and recent findings into the treatment of patients with urothelial cancer.

Target Audience 
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with urothelial cancer.

Learning Objectives

  • Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with advanced urothelial carcinoma, considering the available evidence, and patient and disease characteristics
  • Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors
  • Evaluate biomarkers that accurately predict treatment response and assist in patient selection for personalized therapy
  • Plan therapy for patients with urothelial carcinoma and disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
  • Describe the available data and unique mechanisms of action of novel targeted therapies for the treatment of advanced urothelial carcinoma
  • Discuss ongoing clinical trials investigating targeted systemic therapies and ICI-based combinations for patients across the UC disease spectrum

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
NCCN designates this educational activity for a maximum of 1.5 contact hours.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.5 contact hour (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-20-070-L01-P.

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Attention Pharmacists:
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). Full disclosure of faculty relationships will be made prior to the activity. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.